The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RSV Vaccine Market Research Report 2024
Synopsis
Respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine which prevents infection by respiratory syncytial virus.
Global RSV Vaccine market is projected to reach US$ 261 million in 2029, increasing from US$ 162 million in 2022, with the CAGR of 7.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RSV Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global RSV Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
GSK
Moderna
JNJ
Bavarian Nordic
Nuance Pharma
Advaccine
Segment by Type
Clinical I
Clinical II
Clinical III
Preclinical
Being Developed
Segment by Application
Elderly Vaccine
Infant Vaccine
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The RSV Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine which prevents infection by respiratory syncytial virus.
Global RSV Vaccine market is projected to reach US$ 261 million in 2029, increasing from US$ 162 million in 2022, with the CAGR of 7.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RSV Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global RSV Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
GSK
Moderna
JNJ
Bavarian Nordic
Nuance Pharma
Advaccine
Segment by Type
Clinical I
Clinical II
Clinical III
Preclinical
Being Developed
Segment by Application
Elderly Vaccine
Infant Vaccine
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The RSV Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 RSV Vaccine Market Overview
1.1 Product Overview and Scope of RSV Vaccine
1.2 RSV Vaccine Segment by Type
1.2.1 Global RSV Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Clinical I
1.2.3 Clinical II
1.2.4 Clinical III
1.2.5 Preclinical
1.2.6 Being Developed
1.3 RSV Vaccine Segment by Application
1.3.1 Global RSV Vaccine Market Value by Application: (2023-2029)
1.3.2 Elderly Vaccine
1.3.3 Infant Vaccine
1.3.4 Others
1.4 Global RSV Vaccine Market Size Estimates and Forecasts
1.4.1 Global RSV Vaccine Revenue 2018-2029
1.4.2 Global RSV Vaccine Sales 2018-2029
1.4.3 Global RSV Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 RSV Vaccine Market Competition by Manufacturers
2.1 Global RSV Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global RSV Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global RSV Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global RSV Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of RSV Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of RSV Vaccine, Product Type & Application
2.7 RSV Vaccine Market Competitive Situation and Trends
2.7.1 RSV Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest RSV Vaccine Players Market Share by Revenue
2.7.3 Global RSV Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RSV Vaccine Retrospective Market Scenario by Region
3.1 Global RSV Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global RSV Vaccine Global RSV Vaccine Sales by Region: 2018-2029
3.2.1 Global RSV Vaccine Sales by Region: 2018-2023
3.2.2 Global RSV Vaccine Sales by Region: 2024-2029
3.3 Global RSV Vaccine Global RSV Vaccine Revenue by Region: 2018-2029
3.3.1 Global RSV Vaccine Revenue by Region: 2018-2023
3.3.2 Global RSV Vaccine Revenue by Region: 2024-2029
3.4 North America RSV Vaccine Market Facts & Figures by Country
3.4.1 North America RSV Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America RSV Vaccine Sales by Country (2018-2029)
3.4.3 North America RSV Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe RSV Vaccine Market Facts & Figures by Country
3.5.1 Europe RSV Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe RSV Vaccine Sales by Country (2018-2029)
3.5.3 Europe RSV Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific RSV Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific RSV Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific RSV Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific RSV Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America RSV Vaccine Market Facts & Figures by Country
3.7.1 Latin America RSV Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America RSV Vaccine Sales by Country (2018-2029)
3.7.3 Latin America RSV Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa RSV Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa RSV Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa RSV Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa RSV Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global RSV Vaccine Sales by Type (2018-2029)
4.1.1 Global RSV Vaccine Sales by Type (2018-2023)
4.1.2 Global RSV Vaccine Sales by Type (2024-2029)
4.1.3 Global RSV Vaccine Sales Market Share by Type (2018-2029)
4.2 Global RSV Vaccine Revenue by Type (2018-2029)
4.2.1 Global RSV Vaccine Revenue by Type (2018-2023)
4.2.2 Global RSV Vaccine Revenue by Type (2024-2029)
4.2.3 Global RSV Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global RSV Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global RSV Vaccine Sales by Application (2018-2029)
5.1.1 Global RSV Vaccine Sales by Application (2018-2023)
5.1.2 Global RSV Vaccine Sales by Application (2024-2029)
5.1.3 Global RSV Vaccine Sales Market Share by Application (2018-2029)
5.2 Global RSV Vaccine Revenue by Application (2018-2029)
5.2.1 Global RSV Vaccine Revenue by Application (2018-2023)
5.2.2 Global RSV Vaccine Revenue by Application (2024-2029)
5.2.3 Global RSV Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global RSV Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer RSV Vaccine Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK RSV Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Moderna
6.3.1 Moderna Corporation Information
6.3.2 Moderna Description and Business Overview
6.3.3 Moderna RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Moderna RSV Vaccine Product Portfolio
6.3.5 Moderna Recent Developments/Updates
6.4 JNJ
6.4.1 JNJ Corporation Information
6.4.2 JNJ Description and Business Overview
6.4.3 JNJ RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 JNJ RSV Vaccine Product Portfolio
6.4.5 JNJ Recent Developments/Updates
6.5 Bavarian Nordic
6.5.1 Bavarian Nordic Corporation Information
6.5.2 Bavarian Nordic Description and Business Overview
6.5.3 Bavarian Nordic RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bavarian Nordic RSV Vaccine Product Portfolio
6.5.5 Bavarian Nordic Recent Developments/Updates
6.6 Nuance Pharma
6.6.1 Nuance Pharma Corporation Information
6.6.2 Nuance Pharma Description and Business Overview
6.6.3 Nuance Pharma RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Nuance Pharma RSV Vaccine Product Portfolio
6.6.5 Nuance Pharma Recent Developments/Updates
6.7 Advaccine
6.6.1 Advaccine Corporation Information
6.6.2 Advaccine Description and Business Overview
6.6.3 Advaccine RSV Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Advaccine RSV Vaccine Product Portfolio
6.7.5 Advaccine Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 RSV Vaccine Industry Chain Analysis
7.2 RSV Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 RSV Vaccine Production Mode & Process
7.4 RSV Vaccine Sales and Marketing
7.4.1 RSV Vaccine Sales Channels
7.4.2 RSV Vaccine Distributors
7.5 RSV Vaccine Customers
8 RSV Vaccine Market Dynamics
8.1 RSV Vaccine Industry Trends
8.2 RSV Vaccine Market Drivers
8.3 RSV Vaccine Market Challenges
8.4 RSV Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
